Product image of Icalziss (Calcium Chloride Dihydrate) supplied by GNH India

Icalziss

Active Ingredient:
Calcium Chloride Dihydrate
Origin:
EU

Icalziss (Calcium Chloride Dihydrate)

Calcium chloride dihydrate, the active ingredient in Icalziss, is an electrolyte presented as a solution for extracorporeal use. It restores calcium balance during dialysis and other extracorporeal procedures in patients with renal impairment.
GNH India supplies Icalziss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Vantive Belgium

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icalziss is used to address calcium deficits in the extracorporeal dialysis setting and related renal replacement therapies.

  • Dialysis‑associated hypocalcemia: restores ionized calcium levels during hemodialysis sessions.
  • Extracorporeal circuit calcium balance: maintains optimal calcium concentration in the dialysis circuit.
  • Renal replacement therapy: provides calcium supplementation for patients with impaired renal function undergoing continuous therapies.

How It Works

  • Calcium chloride dihydrate dissociates in solution, releasing calcium ions (Ca²⁺) that readily diffuse into the extracorporeal fluid. The increase in ionized calcium helps correct hypocalcemia, supports coagulation cascade function, and stabilises membrane potentials, thereby re‑establishing calcium homeostasis during dialysis and other extracorporeal procedures.

Side Effects

Icalziss may be associated with a range of adverse reactions, most of which are related to calcium excess or infusion‑related irritation.

Common Side Effects

  • Local irritation at the infusion site: mild redness or discomfort.
  • Transient hypercalcemia: temporary elevation of serum calcium.
  • Hypotension: occasional drop in blood pressure during infusion.
  • Nausea: mild gastrointestinal upset.
  • Muscle cramps: brief, self‑limiting spasms.
  • Headache: mild to moderate intensity.

Serious or Rare Side Effects

  • Severe hypercalcemia: marked elevation of calcium requiring medical intervention.
  • Cardiac arrhythmias: irregular heart rhythms linked to calcium imbalance.
  • Vascular calcification: deposition of calcium in blood vessels with prolonged exposure.
  • Acute pulmonary edema: fluid accumulation in lungs due to rapid calcium shifts.
  • Anaphylactic reaction: rare severe allergic response.
  • Metabolic alkalosis: disturbance of acid‑base balance.

Precautions & Warnings

When using Icalziss, clinicians should observe specific safety measures to minimise risks.

  • Monitor serum calcium levels: check before, during, and after infusion.
  • Assess cardiac function: observe ECG for arrhythmias, especially in patients with heart disease.
  • Adjust dose in renal impairment: consider residual kidney function and dialysis settings.
  • Avoid concurrent high calcium intake: limit dietary or supplemental calcium sources.
  • Use with caution in patients with vascular disease: risk of calcification.
  • Store below 25°C: keep in original container, protect from moisture and direct sunlight.

Avoid Interactions

Calcium chloride can interact with several medications, altering their efficacy or safety profile.

Major Interactions (Avoid)

  • Bisphosphonates: concurrent use may precipitate severe hypocalcemia.
  • Vitamin D analogues (calcitriol, alfacalcidol): increase risk of hypercalcemia.
  • Loop diuretics (furosemide): may enhance calcium loss, requiring close monitoring.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors: monitor blood pressure and renal function.
  • Beta‑blockers: observe for additive effects on heart rate.
  • Other electrolytes (magnesium, phosphate): maintain balanced levels to avoid precipitation.
  • Antacids containing aluminum or magnesium: may affect calcium absorption.
  • Quinolone antibiotics: calcium can reduce their bioavailability.

Frequently Asked Questions

Icalziss is a calcium chloride dihydrate solution used to replenish calcium levels during extracorporeal procedures such as hemodialysis. It helps maintain calcium balance in patients with renal impairment who are at risk of hypocalcemia during dialysis.

The compound dissociates in the solution, releasing calcium ions (Ca²⁺) that diffuse into the extracorporeal circuit. This raises ionised calcium concentrations, correcting hypocalcemia, supporting coagulation, and stabilising cellular membrane potentials during dialysis.

The dose of Icalziss is determined by the prescribing clinician based on the patient’s serum calcium level, dialysis prescription, and overall clinical condition. Specific dosing regimens are individualized and should follow institutional protocols.

Safety data for calcium chloride dihydrate in pregnancy or lactation are limited. Use only if the potential benefit justifies any potential risk to the fetus or infant, and after a careful risk‑benefit assessment by the treating physician.

To order Icalziss, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Icalziss provides calcium in a readily soluble chloride form, allowing rapid correction of calcium deficits in the extracorporeal circuit. Compared with calcium gluconate or calcium carbonate, the chloride salt has a higher elemental calcium content and does not introduce additional anions that could affect acid‑base balance.

Icalziss should be stored below 25 °C, in its original packaging, protected from moisture and direct sunlight. Ensure the container is sealed tightly to prevent contamination and check the expiry date before use.

Icalziss is added to the dialysis circuit or administered intravenously as directed by the dialysis protocol. The solution is introduced into the extracorporeal line, and infusion rates are adjusted according to real‑time calcium monitoring.

The most serious risks include severe hypercalcemia, which can lead to cardiac arrhythmias, vascular calcification, and metabolic alkalosis. Prompt monitoring of serum calcium and cardiac status is essential to detect and manage these complications early.

Icalziss should be avoided in patients with known hypersensitivity to calcium chloride, uncontrolled hypercalcemia, severe vascular calcification, or those receiving high‑dose calcium‑containing medications without appropriate monitoring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Calcium Chloride Dihydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT